Refine by
Arthritis Rheumatoid Articles & Analysis
46 news found
Inhibition of this enzyme can produce therapeutic effects in disease states like cancer, rheumatoid arthritis, and cardiovascular disease. Creative Enzymes is known in the enzyme industry for providing a comprehensive range of enzymes, especially for its hydrolases category. ...
Autoimmune Diseases: Antibodies are designed to modulate the immune response in conditions like rheumatoid arthritis and multiple sclerosis. 3. Infectious Diseases: Antibodies are developed against rapidly evolving pathogens, such as the influenza virus and SARS-CoV-2. ...
Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by suppressing the immune system and reducing inflammation in the body. ...
Walid joined the company in early 2017 and led it through a critical and transformative phase, including the successful completion of the Phase 3 studies of filgotinib in rheumatoid arthritis and ulcerative colitis. We recognize his important contribution to building out the development organization and to bringing our company to the fully integrated biotech that ...
“The recommendation by the PRAC reflects the concerns raised by the substance class mainly in older patients with rheumatoid arthritis,” said Dr. Stefan Schreiber, Professor of Medicine and Gastroenterology at the Christian-Albrechts-University in Kiel, Director of the Clinic for Internal Medicine at the University Hospital Schleswig-Holstein and ...
Walid Abi-Saab, Chief Medical officer, at Galapagos said, “We are excited to present data at ACR which highlights our continued commitment to patients and the healthcare provider community, in particular initial data from our first international, real-world arthritis study. We believe that it’s not only important to control disease activity to prevent long term ...
Q3 2022 operational review and recent events Jyseleca commercial & regulatory progress Strong adoption across Europe with reimbursement for rheumatoid arthritis (RA) in 15 countries and for ulcerative colitis (UC) in 10 countries Marketing Authorization Application (MAA) submitted for the treatment of UC to Swissmedic, the regulatory authority in ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner, GSK plc (LSE/NYSE: GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (RA). The ContRAst phase IIl program enrolled a broad range of difficult-to-treat patients who had an inadequate response to ...
The nationally representative survey estimates that more than 72.3 million U.S. adults – 28% of the adult population – suffer from chronic low back pain (CLBP), higher than previously reported1,2, and greater than arthritis (58.5 million),3 diabetes (37.3 million),4 or heart disease (30.3 million).5 More than three-fourths (76%) say CLBP has interfered with their ...
It is mentioned in the presentation that "Dysregulated interleukin-6 (IL-6) levels underlie several pathological conditions, such as sepsis, progression of cancer, rheumatoid arthritis, and many other conditions. Prior studies indicate that high levels of IL-6 serve as an early indication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced ...
Clinically, active supplementation of glucosamine and chondroitin can relieve the symptoms of arthritis. Therefore, it is widely used to treat osteoarthritis and arthritis pain.D-glucosamine is a monosaccharide containing an amine group instead of a hydroxyl group. ...
Rani conducted a preclinical study of RaniPill HC, with each device containing an 18-mg dose of the biologic adalimumab, a tumor necrosis factor (TNF)-α inhibitor that is approved for multiple autoimmune conditions including rheumatoid arthritis and Crohn’s disease. The unencapsulated RaniPill HC device was placed laparoscopically in the jejunum of ...
The project, titled "A Peptide-Based Polyplex Platform for Nucleotides Delivery to the Sites of Inflammation," will help to move the Company's OligoPhore™ delivery platform towards clinical stage evaluations in inflammatory disorders by demonstrating safety and effectiveness in a mouse model of rheumatoid arthritis and optimizing a commercially scalable ...
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, ...
Chernoff will be invaluable as we advance our rheumatoid arthritis program through the U.S. pivotal study,” commented Murthy Simhambhatla, PhD, President and Chief Executive Officer of SetPoint Medical. ...
Some of the first applications to be commercialized include scanning carotid arteries to assess the risk for stroke, the thyroid and breast to determine whether detected nodules may be malignant, and even assessing and monitoring osteoarthritis and rheumatoid arthritis in the knee, wrist or other parts of the body. “CIMTEC is very excited about the ...
This achievement is significant in that it will be the first global clinical trial among the microbiome treatments for rheumatoid arthritis and NASH indications. The most noteworthy part is that LB-P6 has no toxic effects, even after long-term administration, as no side effects were found compared to existing rheumatoid ...
The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “inflammatory reflex,” for rheumatoid arthritis (RA), Crohn’s disease and other chronic autoimmune diseases as a safe, cost-effective alternative to drugs and biologics. ...
SFA is focused on proprietary drugs to treat chronic inflammation, which been implicated in a wide range of diseases, including Hepatocellular Carcinoma (liver cancer), Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn’s Disease, and Chronic Liver Disease. ...
Baricitinib is approved for the treatment of rheumatoid arthritis and other diseases. It is administered orally and additional research is ongoing to further evaluate the potential role of baricitinib in COVID-19, including NIAID's ACTT-4 trial (assessing the efficacy and safety of baricitinib or dexamethasone in combination with remdesivir in hospitalised adults ...